

August 11, 2022
Web Announcement 2868

Drug Use Review (DUR) Board Approves Changes Effective August 1, 2022.

The Nevada Medicaid Drug Use Review (DUR) Board met on April 28, 2022, and voted to adopt the following changes effective August 1, 2022:

Drug Class/Program	Changes
Respiratory and Allergy Biologic Agents	Addition of new clinical criteria to Xolair® (omalizumab) for the indication of Nasal Polyps
Sedative Hypnotics	Addition of new clinical criteria to Hetlioz® (tasimelteon) for indication of nighttime sleep disturbances in Smith-Magenis Syndrome (SMS)
Movement Disorder Agents	Addition of new clinical criteria to Ingrezza® (valbenazine) for the indication of Tardive Dyskinesia
Ophthalmic Agents, Intraocular Pressure (IOP)-Modifying	Addition of new prior authorization criteria for Vuity® (pilocarpine) 1.25%

Prior Authorization forms may be found on the pharmacy webpage:
<https://nevadamedicaid.magellanrx.com/provider/forms>